HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 301–400 of 1,000
Hypoxia/HIF Modulates Immune Responses
Chen, Y., & Gaber, T. (2021) · Biomedicines · doi:10.3390/biomedicines9030260 · Cited by 119
Lee, B.-R., Chang, S.-Y., Hong, E.-H., Kwon, B.-E., Kim, H. M., Kim, Y.-J., Lee, J., Cho, H.-J., Cheon, J.-H., & Ko, H.-J. (2014) · Oncotarget · doi:10.18632/oncotarget.2589 · Cited by 98
Self-citationFBXW7α attenuates inflammatory signalling by downregulating C/EBPδ and its target gene Tlr4
Balamurugan, K., Sharan, S., Klarmann, K. D., Zhang, Y., Coppola, V., Summers, G. H., Roger, T., Morrison, D. K., Keller, J. R., & Sterneck, E. (2013) · Nature Communications · doi:10.1038/ncomms2677 · Cited by 94
Hypoxia-mediated regulation of macrophage functions in pathophysiology
Riboldi, E., Porta, C., Morlacchi, S., Viola, A., Mantovani, A., & Sica, A. (2012) · International Immunology · doi:10.1093/intimm/dxs110 · Cited by 97
Alleviating hypoxia to improve cancer immunotherapy
Fan, P., Zhang, N., Candi, E., Agostini, M., Piacentini, M., Bernassola, F., Bove, P., Alessandro, M., Giuseppe, N., Valentina, R., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02869-2 · Cited by 104
Opposing Roles for Complement Component C5a in Tumor Progression and the Tumor Microenvironment
Gunn, L., Ding, C., Liu, M., Ma, Y., Qi, C., Cai, Y., Hu, X., Aggarwal, D., Zhang, H., & Yan, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200846 · Cited by 118
Nanoparticles mediated tumor microenvironment modulation: current advances and applications
Raju, G. S. R., Pavitra, E., Varaprasad, G. L., Bandaru, S. S., Nagaraju, G. P., Farran, B., Huh, Y. S., & Han, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01476-9 · Cited by 107
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95
Antigen specificity of immune suppression by myeloid-derived suppressor cells
Solito, S., Bronte, V., & Mandruzzato, S. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0111021 · Cited by 95
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 107
Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs)
Sica, A., Porta, C., Morlacchi, S., Banfi, S., Strauss, L., Rimoldi, M., Totaro, M. G., & Riboldi, E. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0091-6 · Cited by 101
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Law, A. M. K., Lim, E., Ormandy, C. J., & Gallego‐Ortega, D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0404 · Cited by 120
Hao, X., Ren, Y., Feng, M., Wang, Q., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111798 · Cited by 106
Wu, P., Han, J., Gong, Y., Liu, C., Yu, H., & Xie, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101990 · Cited by 111
Gehad, A. E., Lichtman, M. K., Schmults, C. D., Teague, J. E., Calarese, A. W., Jiang, Y., Watanabe, R., & Clark, R. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.190 · Cited by 103
The immunobiology of myeloid-derived suppressor cells in cancer
Motallebnezhad, M., Jadidi‐Niaragh, F., Qamsari, E. S., Bagheri, S., Gharibi, T., & Yousefi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4477-9 · Cited by 97
Metabolic reprograming of tumor-associated macrophages
Puthenveetil, A., & Dubey, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2037 · Cited by 107
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 104
Distinct roles of TREM2 in central nervous system cancers and peripheral cancers
Zhong, J., Xing, X., Gao, Y., Pei, L., Lu, C., Sun, H., Lai, Y., Du, K., Xiao, F., Yang, Y., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.001 · Cited by 109
Sawant, A., & Ponnazhagan, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0305 · Cited by 94
Ji, J., Xu, J., Zhao, S., Liu, F., Qi, J., Song, Y., Ren, J., Wang, T., Dou, H., & Hou, Y. (2016) · Clinical Science · doi:10.1042/cs20160311 · Cited by 92
HIF-mediated innate immune responses: cell signaling and therapeutic implications
Walmsley, S. R., Harris, A. J., Thompson, A. A. R., & Whyte, M. K. B. (2014) · Hypoxia · doi:10.2147/hp.s50269 · Cited by 101
Spinetti, T., Spagnuolo, L., Mottas, I., Secondini, C., Treinies, M., Rüegg, C., Hotz, C., & Bourquin, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1230578 · Cited by 104
Roles of STAT3 in the pathogenesis and treatment of glioblastoma
Fu, W., Hou, X., Dong, L., & Hou, W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1098482 · Cited by 105
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
Park, H. J., Kusnadi, A., Lee, E.-J., Kim, W. W., Cho, B. C., Lee, I. J., Seong, J., & Ha, S.-J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.001 · Cited by 90
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 96
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 98
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P. D. A., Delgoffe, G. M., & Curran, M. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Moreira, D., Sampath, S., Won, H., White, S. V., Su, Y., Alcantara, M. B., Wang, C., Lee, P. P., Maghami, E. G., Massarelli, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137001 · Cited by 94
Macrophage function in the elderly and impact on injury repair and cancer
Duong, L., Radley‐Crabb, H. G., Lee, B. R., Dye, D. E., Pixley, F. J., Grounds, M. D., Nelson, D. J., & Jackaman, C. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00215-2 · Cited by 107
Myeloid-derived suppressor cells in transplantation and cancer
Ochando, J., & Chen, S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8335-1 · Cited by 94
Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 86
Liu, Y., Perego, M., Xiao, Q., He, Y., Fu, S., He, J., Liu, W., Li, X., Tang, Y., Li, X., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128164 · Cited by 92
Self-citationLim, H. X., Kim, T. S., & Poh, C. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103599 · Cited by 89
Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity
Dai, J., Gazzar, M. E., Li, G. Y., Moorman, J. P., & Yao, Z. Q. (2014) · Journal of Innate Immunity · doi:10.1159/000368233 · Cited by 93
Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages
Alaluf, E., Vokaer, B., Detavernier, A., Azouz, A., Splittgerber, M., Carrette, A., Boon, L., Libert, F., Soares, M. P., Moine, A. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133929 · Cited by 113
Lin, X., Zheng, W., Liu, J., Zhang, Y., Qin, H., Wu, H., Xue, B., Lu, Y., & Shen, P. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4617 · Cited by 85
Tumor regulation of the tissue environment in the liver
Eggert, T., & Greten, T. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.005 · Cited by 93
Photodynamic Therapy and Immune Checkpoint Blockade†
Cramer, G. M., Moon, E. K., Cengel, K. A., & Busch, T. M. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13300 · Cited by 93
Lin, L., Kane, N., Kobayashi, N., Kono, E. A., Yamashiro, J. M., Nickols, N. G., & Reiter, R. E. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2293 · Cited by 95
Linking tumour angiogenesis and tumour immunity
Kabir, A. U., Subramanian, M., Kwon, Y., & Choi, K. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01211-z · Cited by 110
Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance
Sierra, R. A., Trillo-Tinoco, J., Mohamed, E. T., Yu, L. C., Achyut, B. R., Arbab, A. S., Bradford, J. W., Osborne, B. A., Miele, L., & Rodrı́guez, P. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0357 · Cited by 82
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 90
Macrophages in tumor: An inflammatory perspective
Goswami, K. K., Bose, A., & Baral, R. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108875 · Cited by 93
Role of myeloid-derived suppressor cells in autoimmune disease
Crook, K. R., & Liu, P. (2014) · World Journal of Immunology · doi:10.5411/wji.v4.i1.26 · Cited by 86
Schouppe, E., BAETSELIER, P. D., Ginderachter, J. A. V., & Sarukhan, A. (2012) · OncoImmunology · doi:10.4161/onci.21566 · Cited by 89
Won, W.-J., Deshane, J. S., Leavenworth, J. W., Oliva, C. R., & Griguer, C. E. (2019) · Cell Stress · doi:10.15698/cst2019.02.176 · Cited by 87
The Macrophage Response Is Driven by Mesenchymal Stem Cell-Mediated Metabolic Reprogramming
Luque-Campos, N., Bustamante-Barrientos, F. A., Pradenas, C., García, C., Araya, M. J., Bohaud, C., Contreras-López, R., Elizondo-Vega, R., Djouad, F., Luz-Crawford, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624746 · Cited by 82
Sharma, A., Sinha, S., & Shrivastava, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849040 · Cited by 93
Zhang, X., Ashcraft, K. A., Warner, A. B., Nair, S. K., & Dewhirst, M. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2468 · Cited by 97
Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site
Nasrollahzadeh, E., Razi, S., Keshavarz‐Fathi, M., Mazzone, M., & Rezaei, N. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02616-6 · Cited by 89
Narita, Y., Kitamura, H., Wakita, D., Sumida, K., Masuko, K., Terada, S., Nakano, K., & Nishimura, T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1103797 · Cited by 81
Farsaci, B., Donahue, R. N., Coplin, M. A., Grenga, I., Lepone, L. M., Molinolo, A. A., & Hodge, J. W. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0076 · Cited by 81
Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment
Kho, V. M., Mekers, V. E., Span, P. N., Bussink, J., & Adema, G. J. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104298 · Cited by 93
Ibrahim, A., Abdalsalam, N. M. F., Liang, Z., Tariq, H. K., Li, R., Afolabi, L. O., Rabiu, L., Chen, X., Xu, S., Xu, Z., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00886-9 · Cited by 101
Myeloid-derived suppressor cells and tumor escape from immune surveillance
Umansky, V., Blattner, C., Fleming, V., Hu, X., Gebhardt, C., Altevogt, P., & Utikal, J. S. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0597-6 · Cited by 85
MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 84
Chang, C.-Y., You, R., Armstrong, D., Bandi, A., Cheng, Y.-T., Burkhardt, P. M., Becerra-Dominguez, L., Madison, M. C., Tung, H.-Y., Zeng, Z., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq0615 · Cited by 86
Metabolic regulation of immunity in the tumor microenvironment
Li, S., Zhang, Y., Tong, H., Sun, H., Liao, H., Li, Q., & Ma, X. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116463 · Cited by 100
Kaimala, S., Mohamed, Y. A., Nader, N., Issac, J. M., Elkord, E., Chouaïb, S., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1543-x · Cited by 89
Olsson, A., Nakhlé, J., Sundstedt, A., Plas, P., Bauchet, A.-L., Pierron, V., Bruetschy, L., Deronic, A., Törngren, M., Liberg, D., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0098-5 · Cited by 78
Dufait, I., Schwarze, J. K., Liechtenstein, T., Leonard, W., Jiang, H., Escors, D., Ridder, M. D., & Breckpot, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3682 · Cited by 89
Lu, Y., Liu, H., Bi, Y., Yang, H., Li, Y., Wang, J., Zhang, Z., Wang, Y., Li, C., Jia, A., et al. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.5 · Cited by 80
Shime, H., Maruyama, A., Yoshida, S., Takeda, Y., Matsumoto, M., & Seya, T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373231 · Cited by 83
Chimal-Ramírez, G. K., Espinoza‐Sánchez, N. A., & Fuentes‐Pananá, E. M. (2013) · Journal of Oncology · doi:10.1155/2013/835956 · Cited by 88
Gr1intCD11b+ Myeloid-Derived Suppressor Cells in Mycobacterium tuberculosis Infection
Obregón-Henao, A., Henao-Tamayo, M., Orme, I. M., & Ordway, D. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080669 · Cited by 74
Energy metabolic pathways control the fate and function of myeloid immune cells
Al-Khami, A. A., Rodríguez, P. C., & Ochoa, A. C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.1vmr1216-535r · Cited by 80
Yuan, S.-J., Xu, Y., Wang, C., An, H.-C., Xu, H., Li, K., Komatsu, N., Zhao, L., & Chen, X. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0541-8 · Cited by 77
Cresswell, G. M., Wang, B., Kischuk, E. M., Broman, M. M., Alfar, R. A., Vickman, R. E., Dimitrov, D. S., Kularatne, S. A., Sundaram, C. P., Singhal, S. K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1414 · Cited by 85
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 87
Khouzam, R. A., Zaarour, R. F., Brodaczewska, K. K., Azakir, B., Venkatesh, G. H., Thiery, J., Terry, S., & Chouaïb, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828875 · Cited by 83
Fernandez, I. E., Greiffo, F. R., Frankenberger, M., Bandres, J., Heinzelmann, K., Neurohr, C., Hatz, R., Hartl, D., Behr, J., & Eickelberg, O. (2016) · European Respiratory Journal · doi:10.1183/13993003.01826-2015 · Cited by 75
Role of OGR1 in myeloid-derived cells in prostate cancer
Yan, L., Singh, L. S., Zhang, L. Z. J., & Xu, Y. (2012) · Oncogene · doi:10.1038/onc.2012.566 · Cited by 80
Hammami, I., Chen, J., Murschel, F., Bronte, V., De Crescenzo, G., & Jolicoeur, M. (2012) · BMC Cell Biology · doi:10.1186/1471-2121-13-18 · Cited by 75
Porphyromonas gingivalis: keeping the pathos out of the biont
Cugini, C., Klepac‐Ceraj, V., Rackaityte, E., Riggs, J. E., & Davey, M. E. (2013) · Journal of Oral Microbiology · doi:10.3402/jom.v5i0.19804 · Cited by 89
Molecular Regulation of Bone Metastasis Pathogenesis
Wu, M., Li, C.-J., Yiang, G., Cheng, Y., Tsai, A. P., Hou, Y.-T., Ho, Y.-C., Hou, M., & Chu, P. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489184 · Cited by 79
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 80
Zhu, G., Tang, Y., Geng, N., Zheng, M. H., Jiang, J. D., Li, L., Li, K., Lei, Z., Chen, W., Fan, Y., et al. (2014) · Neoplasia · doi:10.1593/neo.132034 · Cited by 77
Targeting stroma to treat cancers
Engels, B., Rowley, D. A., & Schreiber, H. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.008 · Cited by 74
One microenvironment does not fit all: heterogeneity beyond cancer cells
Kim, I. S., & Zhang, X. H.-F. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9643-z · Cited by 79
Maenhout, S. K., Van Lint, S., Emeagi, P. U., Thielemans, K., & Aerts, J. L. (2014) · International Journal of Cancer · doi:10.1002/ijc.28449 · Cited by 73
“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
Liu, K. X., & Joshi, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01947 · Cited by 84
Zheng, Y., Wang, N., Wang, S., Zhang, J., Yang, B., & Wang, Z. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02696-z · Cited by 88
Parker, K. H., Horn, L. A., & Ostrand‐Rosenberg, S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi0715-305r · Cited by 76
Hypoxic Microenvironment and Metastatic Bone Disease
Hiraga, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113523 · Cited by 82
Botta, C., Gullà, A., Correale, P., Tagliaferri, P., & Tassone, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00348 · Cited by 76
pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma
Kuchuk, O., Tuccitto, A., Citterio, D., Huber, V., Camisaschi, C., Milione, M., Vergani, B., Villa, A., Alison, M. R., Carradori, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445452 · Cited by 75
TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis
Yan, D., Wang, J., Sun, H., Zamani, A., Zhang, H., Chen, W., Tang, A., Ruan, Q., Yang, X., Chen, Y. H., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182005 · Cited by 78
Deng, Y., Shi, M., Lin, Y., Khan, M. N., Xia, Z., & Li, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37060 · Cited by 75
The emerging role of myeloid-derived suppressor cells in lung diseases
Kolahian, S., Öz, H. H., Zhou, B., Griessinger, C. M., Rieber, N. P., & Hartl, D. (2016) · European Respiratory Journal · doi:10.1183/13993003.01572-2015 · Cited by 80
Ostrand‐Rosenberg, S., Horn, L. A., & Ciavattone, N. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00215 · Cited by 77
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557586 · Cited by 84
Yuan, C.-S., Deng, Z., Qin, D., Mu, Y., Chen, X., & Liu, Y. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.02.030 · Cited by 72
Medina‐Echeverz, J., Haile, L. A., Zhao, F., Gamrekelashvili, J., Ma, C., Métais, J., Dunbar, C. E., Kapoor, V., Manns, M. P., Korangy, F., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444497 · Cited by 71
De Sanctis, F., Sandri, S., Ferrarini, G., Pagliarello, I., Sartoris, S., Ugel, S., Marigo, I., Molon, B., & Bronte, V. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00069 · Cited by 71
Sorrentino, R., Morello, S., Forte, G., Montinaro, A., Vita, G. D., Luciano, A., Palma, G., Arra, C., Maiolino, P., Adcock, I. M., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201010-1738oc · Cited by 76
Younis, R., Han, K., & Webb, T. (2016) · Journal of Immunology · doi:10.4049/jimmunol.1501293 · Cited by 67
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
Li, L., & Tian, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114504 · Cited by 79
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.